about
Adapting the DOTS framework for tuberculosis control to the management of non-communicable diseases in sub-Saharan AfricaThe rate of sputum smear-positive tuberculosis after treatment default in a high-burden setting: a retrospective cohort studyMultidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsThe influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosisDevelopment and implementation of a national programme for the management of severe and very severe pneumonia in children in Malawi.Glycemic control and radiographic manifestations of tuberculosis in diabetic patientsCritical evaluation of the Global DOTS Expansion Plan.High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa.Are children with tuberculosis in Pakistan managed according to National programme policy guidelines? A study from 3 districts in PunjabTreatment delay among tuberculosis patients in Tanzania: data from the FIDELIS initiative.Indoor solid fuel use and tuberculosis in China: a matched case-control study.Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India.Operational challenges in managing Isoniazid Preventive Therapy in child contacts: a high-burden setting perspectiveA comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert® MTB/RIF-based algorithms in a routine operational setting in Cape Town.Childhood tuberculosis deskguide and monitoring: an intervention to improve case management in PakistanOutcomes of TB treatment by HIV status in national recording systems in Brazil, 2003-2008.Can follow-up examination of tuberculosis patients be simplified? A study in Chhattisgarh, IndiaHigh prevalence of tuberculosis and insufficient case detection in two communities in the Western Cape, South Africa.Comparing same day sputum microscopy with conventional sputum microscopy for the diagnosis of tuberculosis--Chhattisgarh, India.Tuberculosis in healthcare workers and infection control measures at primary healthcare facilities in South Africa.LED-fluorescence microscopy for diagnosis of pulmonary tuberculosis under programmatic conditions in IndiaOutcome of tuberculosis treatment in patients with diabetes mellitus treated in the revised national tuberculosis control programme in Malappuram District, Kerala, India.Intensified tuberculosis case finding among malnourished children in nutritional rehabilitation centres of Karnataka, India: missed opportunities.Assessment of a revolving drug fund for essential asthma medicines in BeninUse of the tuberculin skin test in children.Children and the global tuberculosis situation.How far do we still need to go to provide health solutions for the poor?Potentially Modifiable Factors Associated with Death of Infants and Children with Severe Pneumonia Routinely Managed in District Hospitals in Malawi.Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.How do we measure the success of operational research?Drug-resistant tuberculosis transmission and resistance amplification within families.Cochrane systematic review of directly observed therapy for treating tuberculosis: good analysis of the wrong outcome.Chronic airflow limitation in developing countries: burden and priorities.Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.The vital signs of chronic disease management.Health systems that serve: what's the bottom line?Implementing a successful tuberculosis programme within primary care services in a conflict area using the stop TB strategy: Afghanistan case study.Impact of HIV on standard case management for severe pneumonia in children.Challenges to the global control of tuberculosis.The International Union Against Tuberculosis and Lung Disease: past, present and future.
P50
Q21144651-5CF1C481-7F20-4B9D-BA6D-595EED6D39B2Q28389066-8159511D-90DE-46AB-A0C0-FEDA84634E4EQ28482730-07B96133-EEFD-4EE9-AAB2-C41560C1B01CQ28545145-4F6392DE-866C-4FD2-9325-8A6778C486C5Q30878977-DA7B02F1-E78F-4955-A6C4-BF1C58AD51FDQ31156192-58E63B55-BF3E-4805-93A3-C4434B341BC4Q33291171-DFE71B6C-57F7-4448-AEBD-8CB4C63FD225Q33686129-E5F82EDD-7F37-4133-BC58-252216A8461CQ33757952-D5AEFE2C-0244-4B9B-94CF-DE1C06C105B1Q33898943-5FF775B7-17BE-4813-B4D7-E7FD6AE9D641Q33942468-A42464B8-A038-4DB0-B485-7EEDCD018464Q33945862-385B2586-DC00-4C81-B235-FD968D1153D7Q33955943-97EC3296-595A-4610-AA0D-75840DA88F0BQ33982095-7F3A8763-6FEF-4666-BF55-3F7B449FCC23Q33989510-56D9C6C3-ED34-410C-88E2-BECEB7417D55Q34211754-27483871-795D-4789-829F-D3DDD771D685Q34507196-C038BAD6-E581-4D59-A34A-F7B730A7530EQ34656147-7302CC28-7214-4D9A-8EFE-36E2149C0809Q35005281-D572E752-4317-40D3-91FD-81FD250A6CA0Q35009333-1B5B2877-39CA-4CD9-BBE9-E120C07BDE58Q35018320-A7B40D15-56AA-4CFC-84C7-2F81B4AEE2C0Q35025278-7544369E-C90C-43DF-9958-E87A66AD0708Q35073300-C0622598-D3F3-4419-9648-83D53EBC3AB6Q35382074-32199D22-244F-4642-8944-27F239527CEEQ35674164-58076F6D-BFC3-41F3-ABAE-6525D153809AQ35674169-8968A75D-129B-4D2D-93AC-9AE0AB25567FQ35718512-F049362C-BB41-4F89-9651-C5D71D9AD29AQ35734934-AE3B9822-9B85-4B8C-BA4B-4A22E674223DQ35941022-FA3B46E1-7280-4A53-8BED-5EDBD6536014Q35962638-EA92263C-947E-4C2B-9679-821BCF281B97Q36148038-BFAF4524-2097-4B9D-9384-C8E08E72AD3DQ36722297-77F3CA33-907D-4139-AF34-7477274D93A4Q37225477-67C5C2BA-F0BD-4359-BD33-942F1417B1C4Q37306561-88155508-4B04-453D-A512-C3FF9F08FD5EQ37372946-D8D760F1-C139-4B32-AC08-1CA0947B6619Q37531024-2AA92E04-D381-49ED-9C95-1679C1D6BD66Q37580336-03BB47B2-7C03-484F-B4C3-27D48FA44273Q37734447-CA9438C7-6838-4223-90EE-95CB2BC030AAQ38095593-5E4D7BDF-F387-408B-B9FF-14A00D17F150Q38137662-085F0397-6321-4FEE-A928-A78B8734AA43
P50
description
Docteur en médecine. - Directe ...... ires depuis 1991 (en 2005), -
@fr
name
Donald A. Enarson
@ast
Donald A. Enarson
@ca
Donald A. Enarson
@de
Donald A. Enarson
@en
Donald A. Enarson
@es
Donald A. Enarson
@fr
Donald A. Enarson
@ga
Donald A. Enarson
@it
Donald A. Enarson
@nl
Donald A. Enarson
@pt
type
label
Donald A. Enarson
@ast
Donald A. Enarson
@ca
Donald A. Enarson
@de
Donald A. Enarson
@en
Donald A. Enarson
@es
Donald A. Enarson
@fr
Donald A. Enarson
@ga
Donald A. Enarson
@it
Donald A. Enarson
@nl
Donald A. Enarson
@pt
prefLabel
Donald A. Enarson
@ast
Donald A. Enarson
@ca
Donald A. Enarson
@de
Donald A. Enarson
@en
Donald A. Enarson
@es
Donald A. Enarson
@fr
Donald A. Enarson
@ga
Donald A. Enarson
@it
Donald A. Enarson
@nl
Donald A. Enarson
@pt
P1015
P214
P244
P268
P269
P1015
P1412
P21
P213
0000 0000 3082 3244
P214
P244
P268
P269
P27
P31
P735
P7859
lccn-n93802108